Company intelligence / Profile preview

Juvaris BioTherapeutics

Burlingame, California, United Statespitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

Juvaris developed a novel adjuvant platform based on cationic lipid-non-coding DNA complexes, which demonstrated strong T-cell and antibody responses in preclinical models. Its lead adjuvant, JVRS‑100, reached Phase 2 clinical trials as an enhancer for seasonal flu vaccines in the elderly. The company also advanced proprietary vaccine candidates for influenza, hepatitis B, HSV‑2, and pneumonia. In 2011, all human health assets were exclusively licensed to Colby Pharmaceutical Company; animal health rights had been previously licensed to Bayer AG.

Therapeutic areas: Infectious Diseases
Modalities: VaccineAdjuvantLipid nanoparticle delivery therapy
Industry: Biotech

Drug pipeline

1 asset

JuvaVax Influenza A

Discontinued

Partnerships

Colby Pharmaceutical Company (exclusive licensee for human health applications since September 2011)Bayer AG (animal health rights licensee since ~2008)

Beyond the preview

Go deeper on Juvaris BioTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juvaris BioTherapeutics.

Explore the full profile